We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.57%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.28B
AUM Growth
+$165M
(+15%)
Cap. Flow
+$73.1M
Cap. Flow
% of AUM
5.73%
Top 10 Holdings %
Top 10 Hldgs %
52.86%
Holding
80
New
6
Increased
21
Reduced
22
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
+$24.2M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$18.2M |
| 3 |
TELA Bio
TELA
|
+$17.6M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$16.4M |
| 5 |
Outset Medical
OM
|
+$13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLU
BELLUS Health Inc.
BLU
|
+$21.7M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$14.6M |
| 3 |
Krystal Biotech
KRYS
|
+$9.67M |
| 4 |
Keros Therapeutics
KROS
|
+$7.77M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$7.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.83% |
| 2 | Communication Services | 5.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
1
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $146M | 11.45% |
1,432,208
-154,720
| -10% | -$14.6M |
|
2
Prothena Corp
PRTA
$425M
| $102M | 8.03% |
1,500,129
-11,039
| -0.7% | -$712K |
|
3
AtriCure
ATRC
$1.92B
| $72.1M | 5.65% |
1,461,635
+2,578
| +0.2% | +$119K |
|
|
MODN
4
DELISTED
MODEL N, INC.
MODN
| $66M | 5.17% |
1,865,525
+11,852
| +0.6% | +$381K |
|
5
SI-BONE Inc
SIBN
$788M
| $57.1M | 4.47% |
2,114,829
+617
| +0% | +$15K |
|
6
Alphatec Holdings
ATEC
$1.46B
| $53.4M | 4.19% |
2,971,877
+27,752
| +0.9% | +$432K |
|
|
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $45.3M | 3.55% |
208,746
-34,929
| -14% | -$7.48M |
|
8
Orthofix Medical
OFIX
$477M
| $44.4M | 3.48% |
2,459,129
-191,842
| -7% | -$3.58M |
|
|
BCYC
9
Bicycle Therapeutics
BCYC
$269M
| $44.4M | 3.48% |
1,739,449
+1,040,121
| +149% | +$24.2M |
|
10
NeoGenomics
NEO
$1.96B
| $43.3M | 3.39% |
2,692,057
-6,901
| -0.3% | -$114K |
|
|
FNA
11
DELISTED
Paragon 28, Inc.
FNA
| $36.5M | 2.86% |
2,057,307
+19,368
| +1% | +$348K |
|
12
Pliant Therapeutics
PLRX
$64.4M
| $32.8M | 2.57% |
1,810,176
+384,822
| +27% | +$9.11M |
|
13
Health Catalyst
HCAT
$154M
| $31.8M | 2.49% |
2,540,959
+560,642
| +28% | +$6.68M |
|
14
Transmedics
TMDX
$2.64B
| $31.7M | 2.48% |
377,464
+39,552
| +12% | +$3.03M |
|
15
Crinetics Pharmaceuticals
CRNX
$8.84B
| $28.1M | 2.2% |
1,557,222
-61,903
| -4% | -$1.23M |
|
|
16
Ultragenyx Pharmaceutical
RARE
$2.45B
| $27.2M | 2.13% |
589,963
+354,186
| +150% | +$16.4M |
|
17
OptimizeRx
OPRX
$114M
| $26.7M | 2.1% |
1,871,799
+860,868
| +85% | +$12.3M |
|
|
PHLT
18
DELISTED
Performant Healthcare Inc
PHLT
| $25M | 1.96% |
9,249,683
+1,038,984
| +13% | +$3.01M |
|
19
Omnicell
OMCL
$1.61B
| $23.7M | 1.86% |
321,664
-11,845
| -4% | -$799K |
|
|
20
Zentalis Pharmaceuticals
ZNTL
$337M
| $21.4M | 1.68% |
+757,835
| New | +$18.2M |
|
21
Halozyme
HALO
$9.79B
| $21.1M | 1.65% |
584,248
-103,958
| -15% | -$3.55M |
|
22
KORU Medical Systems
KRMD
$189M
| $18.3M | 1.43% |
5,299,639
-891,678
| -14% | -$3.5M |
|
23
Axogen
AXGN
$2.27B
| $18M | 1.41% |
1,973,699
+32,603
| +2% | +$304K |
|
24
Tactile Systems Technology
TCMD
$635M
| $17.7M | 1.39% |
711,345
+11,345
| +2% | +$236K |
|
|
25
TELA Bio
TELA
$32.7M
| $17.5M | 1.37% |
+1,725,500
| New | +$17.6M |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, First Light Asset Management held 80 positions worth $1.28B, up 15% from $1.11B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
First Light Asset Management deployed $73.1M of net new capital in Q2 2023, opening 6 new positions and adding to 21 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 757,835 shares worth $21.4M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Communication Services.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $14.6M trimmed.
- First Light Asset Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 757,835 shares worth $21.4M.
- First Light Asset Management added most to Bicycle Therapeutics in Q2 2023, an estimated $24.2M increase.
- First Light Asset Management's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $14.6M.
- First Light Asset Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $21.7M.
- First Light Asset Management's ten largest holdings make up 53% of its $1.28B portfolio in Q2 2023.
- First Light Asset Management opened 6 new positions and closed 1 in Q2 2023.
- First Light Asset Management's portfolio value rose 15% quarter-over-quarter to $1.28B.
Based on First Light Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.